In a report released yesterday, Tejas Savant from Morgan Stanley maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00. The company’s shares closed last Tuesday at $72.38, close to its 52-week low of $59.57.
According to TipRanks.com, Savant is a 1-star analyst with an average return of -5.1% and a 35.4% success rate. Savant covers the Healthcare sector, focusing on stocks such as Nautilus Biotechnolgy, Akoya Biosciences, and Cytek Biosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Guardant Health with a $119.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Guardant Health’s market cap is currently $7.12B and has a P/E ratio of -17.88.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Read More on GH:
- U.S. Regulators Probe Wall Street Firms for Block Trades – Report
- Natera (NTRA) Receives a Buy from Morgan Stanley
- ICL-Israel Chemicals (ICL) Receives a Hold from Morgan Stanley
- Morgan Stanley Maintains Their Hold Rating on Essex Property (ESS)
- Republic Services (RSG) Gets a Buy Rating from Morgan Stanley
